Nalaganje...
Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer
Overexpression of the HER2/Neu (ErbB2) proto-oncogene is associated with breast cancer progression and poor patient prognosis. Herceptin (trastuzumab) is a humanized IgG1 against the ectodomain of the HER2 receptor. In combination with chemotherapy, it induces regression of HER2-overexpressing metas...
Shranjeno v:
| Glavni avtor: | |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
BioMed Central
2003
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC154152/ https://ncbi.nlm.nih.gov/pubmed/12631388 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|